Austin Chemical Company, Inc

Austin Chemical Company, Inc. was founded in 1976 as a sales and marketing representative company for ingredients, components and raw material primarily to life science companies. We have expanded our activities, supporting not only aspects of Life Sciences but also those of Specialty Fine Chemicals. Representations today include globally based chemical producers and contract manufacturers. SOP's addressing the ever-changing regulatory transportation requirements exist in our key Departments including Customer Service and Logistics, to provide efficient and cost effective product deliveries.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PRODUCTS AND TECHNOLOGIES

H.I.G. CAPITAL PORTFOLIO COMPANY USALCO COMPLETES MERGER WITH G2O TECHNOLOGIES

H.I.G. Capital | November 02, 2021

news image

H.I.G. Capital a leading global alternative investment firm with over $45 billion of equity capital under management, announced today that its portfolio company, USALCO, LLC (“USALCO”), has completed a merger with G2O Technologies LLC (“G2O”), a portfolio company of Arsenal Capital Partners (“Arsenal”). Ken Gayer, the current USALCO CEO, will lead the new company which will continue to bear the name USALCO The USALCO and G2O merger creates one o...

Read More

ST. LUKE'S CONTRIBUTES TO RESEARCH ON MONOCLONAL ANTIBODIES MADE FAMOUS BY PRESIDENT TRUMP'S TREATMENT

Prnewswire | October 09, 2020

news image

Patients who recovered from COVID-19 at St. Luke's University Health Network have donated their antibody-rich blood to medical science in hopes of helping to find an effective treatment or cure to the novel coronavirus that has killed nearly 200,000 Americans. The "convalescent plasma" was separated from the survivors' blood and is being studied as part of a research project labeled AR-701, sponsored by Aridis Pharmaceuticals, a biopharmaceutical firm in San Jose, Ca., th...

Read More

CHEMICAL TECHNOLOGY

AIR LIQUIDE AND BASF WELCOME SUPPORT FROM EUROPEAN INNOVATION FUND FOR JOINT CCS PROJECT

Air Liquide, BASF | November 22, 2021

news image

Air Liquide and BASF are planning to develop the world’s largest cross-border Carbon Capture and Storage (CCS) value chain. The goal is to significantly reduce CO2 emissions at the industrial cluster in the port of Antwerp. The joint project “Kairos@C” has been selected for funding by the European Commission through its Innovation Fund, as one of the seven large-scale projects out of more than 300 applications. Kairos@C will be jointly developed by Air Liquide an...

Read More

NANOCATALYSTS THAT REMOTELY CONTROL CHEMICAL REACTIONS INSIDE LIVING CELLS

Sciencedaily | August 11, 2020

news image

The enzymes responsible for catalytic reactions in our body's biological reactions are difficult to use for diagnosis or treatment as they react only to certain molecules or have low stability. Many researchers anticipate that if these issues are ameliorated or if artificial catalysts are developed to create a synergetic effect by meeting the enzymes in the body, there will be new ways to diagnose and treat diseases. In particular, if artificial catalysts that respond to external stimuli suc...

Read More
news image

PRODUCTS AND TECHNOLOGIES

H.I.G. CAPITAL PORTFOLIO COMPANY USALCO COMPLETES MERGER WITH G2O TECHNOLOGIES

H.I.G. Capital | November 02, 2021

H.I.G. Capital a leading global alternative investment firm with over $45 billion of equity capital under management, announced today that its portfolio company, USALCO, LLC (“USALCO”), has completed a merger with G2O Technologies LLC (“G2O”), a portfolio company of Arsenal Capital Partners (“Arsenal”). Ken Gayer, the current USALCO CEO, will lead the new company which will continue to bear the name USALCO The USALCO and G2O merger creates one o...

Read More
news image

ST. LUKE'S CONTRIBUTES TO RESEARCH ON MONOCLONAL ANTIBODIES MADE FAMOUS BY PRESIDENT TRUMP'S TREATMENT

Prnewswire | October 09, 2020

Patients who recovered from COVID-19 at St. Luke's University Health Network have donated their antibody-rich blood to medical science in hopes of helping to find an effective treatment or cure to the novel coronavirus that has killed nearly 200,000 Americans. The "convalescent plasma" was separated from the survivors' blood and is being studied as part of a research project labeled AR-701, sponsored by Aridis Pharmaceuticals, a biopharmaceutical firm in San Jose, Ca., th...

Read More
news image

CHEMICAL TECHNOLOGY

AIR LIQUIDE AND BASF WELCOME SUPPORT FROM EUROPEAN INNOVATION FUND FOR JOINT CCS PROJECT

Air Liquide, BASF | November 22, 2021

Air Liquide and BASF are planning to develop the world’s largest cross-border Carbon Capture and Storage (CCS) value chain. The goal is to significantly reduce CO2 emissions at the industrial cluster in the port of Antwerp. The joint project “Kairos@C” has been selected for funding by the European Commission through its Innovation Fund, as one of the seven large-scale projects out of more than 300 applications. Kairos@C will be jointly developed by Air Liquide an...

Read More
news image

NANOCATALYSTS THAT REMOTELY CONTROL CHEMICAL REACTIONS INSIDE LIVING CELLS

Sciencedaily | August 11, 2020

The enzymes responsible for catalytic reactions in our body's biological reactions are difficult to use for diagnosis or treatment as they react only to certain molecules or have low stability. Many researchers anticipate that if these issues are ameliorated or if artificial catalysts are developed to create a synergetic effect by meeting the enzymes in the body, there will be new ways to diagnose and treat diseases. In particular, if artificial catalysts that respond to external stimuli suc...

Read More